Study guide
3.1 Hematolymphoid Differentiation & Gating Baselines
ASCP SCYM Specialist in Cytometry Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Flow Cytometry Instrumentation & Biophysics
1.1 Fluidic Systems: Hydrodynamic Focusing, Acoustic Focusing, Laminar Flow & Sheath Dynamics 1.2 Laser Physics, Light Sources & Beam Shaping Optics 1.3 Optical Layout: Dichroic Mirrors, Bandpass Filters & Spatial Separation 1.4 Photo Detectors: PMTs, APDs, Silicon Photomultipliers & Spectral Arrays 1.5 Signal Processing, Pulse Geometry & Preamplifiers 1.6 Analog-to-Digital Conversion (ADC) & Dynamic Range 1.7 Instrument Optical & Fluidic Troubleshooting
2 Chapter 2: Panel & Experiment Design
2.1 Sample Collection, Anticoagulants, Integrity & Stability 2.2 Sample Preparation Protocols: Lyse-No-Wash, Lyse-Wash & Permeabilization 2.3 Cell Enrichment & Isolation Methods 2.4 Fluorochrome Properties, Laser Excitation, Emission Spectra & Tandem Dyes 2.5 Compensation Theory & Spectral Overlap Spreading 2.6 Experimental Controls: FMO, Isotype, Viability & Biological Controls 2.7 Panel Design Architecture & Antigen Density Matching
3 Chapter 3: Clinical Diagnostic Immunophenotyping
3.1 Hematolymphoid Differentiation & Gating Baselines 3.2 Chronic Lymphocytic Leukemia (CLL) & Mature B-Cell Lymphomas 3.3 Plasma Cell Neoplasms & Monoclonal Gammopathies 3.4 Acute Myeloid Leukemia (AML) & Lineage Assignment 3.5 Acute Lymphoblastic Leukemia (B-ALL & T-ALL) Subtyping 3.6 Minimal/Measurable Residual Disease (MRD) Detection 3.7 Primary Immunodeficiencies & Immune Monitoring
4 Chapter 4: Special & Emerging Applications
4.1 Cell Function, Proliferation & Apoptosis Assays 4.2 Multiplex Bead Arrays & Soluble Analyte Quantification 4.3 Solid Organ Transplant & HLA Crossmatching 4.4 Stem Cell Enumeration & ISHAGE Protocol 4.5 Cell Cycle & DNA Content Analysis 4.6 Rare Event & Small Particle (Extracellular Vesicle) Analysis 4.7 Fetal Hemoglobin Assay & Fetomaternal Hemorrhage 4.8 Preparative Cell Sorting: Electrostatic Droplet Deflection & Microfluidics 4.9 Imaging Flow Cytometry: Multispectral Imaging & Spatial Localization 4.10 Mass Cytometry (CyTOF) & Single-Cell Elemental Analysis
5 Chapter 5: Data Analysis, Informatics & High-Dimensional Cytometry
5.1 Data Standards, FCS File Format (FCS 2.0/3.0/3.1) & Metadata 5.2 Data Display & Scaling Transformations (Log, Bi-exponential, Hyperlog, ArcSinh) 5.3 Gating Hierarchy & Population Isolation Strategies 5.4 High-Dimensional Data Reduction (t-SNE, UMAP, PCA) & Automated Clustering 5.5 Common Data Modeling & Population Comparison Metrics 5.6 Quantitative Calibration & Molecules of Equivalent Soluble Fluorochrome (MESF) 5.7 Data Analysis Artifacts & Data Troubleshooting
6 Chapter 6: Quality Control, Quality Assurance & Laboratory Administration
6.1 Daily Quality Control, CS&T Beads & Performance Tracking 6.2 Assay Validation & Verification Standards (CLSI H42-A2, H62) 6.3 Biosafety & Aerosol Containment in Flow Cytometry 6.4 Laboratory Administration, Regulatory Compliance (CLIA, CAP, FDA) & Personnel 6.5 Reagent Qualification, Titration & Stability Testing 6.6 Clinical Correlation & Multidisciplinary Reporting
3.1 Hematolymphoid Differentiation & Gating Baselines
Key Takeaways Explain This Topic AI
CD45 vs SSC gating is the foundational step in clinical flow cytometry to identify major leukocyte populations.
Normal maturation follows strict, reproducible patterns of antigen acquisition and loss.
Malignant cells often exhibit aberrant antigen expression, such as asynchronous expression or lineage infidelity.
Proper gating must include doublet discrimination and dead cell exclusion using viability dyes like 7-AAD.
Last updated: July 2026
Hematolymphoid Differentiation & Gating Baselines
In clinical flow cytometry, understanding normal hematolymphoid differentiation is the foundational step before identifying abnormal populations. The hematolymphoid system arises from pluripotent hematopoietic stem cells (HSCs) in the bone marrow. These HSCs can differentiate into multipotent progenitors, which further commit to either the myeloid or lymphoid lineage. Flow cytometry allows the direct tracking of this differentiation process by analyzing the stepwise expression, loss, and modulation of various cell surface, cytoplasmic, and nuclear antigens.
The most fundamental gating strategy employed in clinical flow cytometry is the CD45 versus Side Scatter (SSC) plot. CD45, also known as the leukocyte common antigen, is a transmembrane glycoprotein expressed on all nucleated hematopoietic cells. Its expression level varies predictably depending on the lineage and maturation stage of the cell. Side scatter (SSC) measures the internal complexity or granularity of a cell. When combined, CD45 and SSC create a robust and highly reproducible map of the major leukocyte populations in peripheral blood and bone marrow.
CD45 vs SSC Gating Strategy
Lymphocytes: Lymphocytes exhibit the highest level of CD45 expression (CD45 bright) and the lowest side scatter (SSC low). This population includes T cells, B cells, and Natural Killer (NK) cells. In a healthy individual, this population is tight and easily identifiable in the CD45 bright / SSC low region.
Monocytes: Monocytes have slightly lower CD45 expression than lymphocytes and higher side scatter due to their moderately granular cytoplasm and irregular nucleus. They are found in the CD45 moderate-high / SSC moderate region.
Granulocytes (Neutrophils, Eosinophils, Basophils): Granulocytes typically have lower CD45 expression than lymphocytes and monocytes, but they possess significantly higher side scatter. Neutrophils form a dense cluster in the CD45 moderate / SSC high area. Eosinophils have even higher side scatter than neutrophils. Basophils are often found between the lymphocyte and monocyte populations with relatively low SSC and moderate CD45.
Blasts (Immature Cells): In normal bone marrow, normal myeloblasts and lymphoblasts are found in the "blast gate," which is characterized by CD45 dim expression and low side scatter. They are located below the lymphocyte population on the CD45 axis. In acute leukemias, the malignant blasts typically expand within this CD45 dim / SSC low region.
Erythroid Precursors and Megakaryocytes: These populations generally lack or have very low CD45 expression. Nucleated red blood cells (nRBCs) fall into the CD45 negative / SSC low region, often overlapping with debris or platelets if not properly gated or lysed.
Understanding these baseline populations is critical. When analyzing a sample for potential malignancy, the flow cytometrist first looks for abnormalities in the distribution of cells on the CD45 vs SSC plot. For example, a massive expansion in the blast gate (CD45 dim / SSC low) immediately raises suspicion for acute leukemia, whereas an expanded CD45 bright / SSC low population might indicate a mature lymphoproliferative disorder such as Chronic Lymphocytic Leukemia (CLL) or a reactive lymphocytosis.
Lineage-Specific Antigens
Beyond CD45, clinical panels employ a wide array of lineage-specific markers.
T-Cell Markers: CD3 (the defining marker, surface or cytoplasmic), CD4 (T helper cells), CD8 (Cytotoxic T cells), CD2, CD5, and CD7.
B-Cell Markers: CD19, CD20, CD22, CD79a (cytoplasmic, highly specific), and surface immunoglobulins (kappa or lambda light chains).
NK-Cell Markers: CD56, CD16, lacking surface CD3.
Myeloid Markers: CD13, CD33, CD11b, CD15, and myeloperoxidase (MPO, cytoplasmic, highly specific for myeloid differentiation).
Monocytic Markers: CD14, CD64, CD11c, and non-specific esterase (NSE).
Megakaryocytic/Platelet Markers: CD41, CD42b, CD61.
Erythroid Markers: CD71, CD235a (Glycophorin A).
Stem Cell/Progenitor Markers: CD34, CD117 (c-kit), TdT (Terminal deoxynucleotidyl transferase, nuclear), and HLA-DR.
Maturation Patterns
Flow cytometric analysis relies heavily on evaluating the synchronous expression of antigens during cell maturation. Normal hematopoiesis follows strict, reproducible patterns of antigen acquisition and loss. For instance, in normal B-cell maturation in the bone marrow (hematogones), the earliest B-cell precursors express CD34, TdT, CD19, and bright CD10, but lack CD20 and surface immunoglobulin. As they mature, they downregulate CD34 and TdT, upregulate CD20, modulate CD10, and eventually acquire surface IgM and IgD.
Malignant cells frequently exhibit aberrant antigen expression . This can take several forms:
Asynchronous expression: Co-expression of early and late markers (e.g., CD34 expressed simultaneously with CD20 on a B-cell).
Lineage infidelity (cross-lineage expression): Expression of markers from another lineage (e.g., a myeloid blast expressing the lymphoid marker CD7).
Antigen overexpression or underexpression: Uniformly brighter or dimmer expression than normally seen (e.g., abnormally dim CD45 on a mature lymphocyte).
Absence of a normally expressed antigen: Such as the lack of CD13 on a myeloid blast.
Identifying these aberrations is the cornerstone of minimal/measurable residual disease (MRD) detection, which will be discussed in later sections.
Practical Considerations in Gating
Accurate gating requires careful exclusion of debris, dead cells, and doublets.
Doublet Discrimination: Forward scatter area (FSC-A) versus forward scatter height (FSC-H) or width (FSC-W) is used to exclude cell aggregates (doublets). Doublets can create false-positive dual-expressing populations (e.g., a T-cell and a B-cell stuck together appearing as a CD3+/CD19+ cell).
Viability Dyes: Dead cells can non-specifically bind antibodies, leading to false-positive signals. Dyes like 7-AAD, Propidium Iodide (PI), or amine-reactive viability dyes are used to gate out dead cells. Dead cells take up these dyes, while live cells exclude them.
Fluorescence Minus One (FMO) Controls: In complex multicolour panels, FMO controls (containing all antibodies except one) are crucial for determining the exact boundary between positive and negative populations, especially for continuous or dim markers. This accounts for fluorescence spillover (spreading error) from other fluorochromes in that specific channel.